We report the results of 84 patients with ALL after related (n ¼ 46) or unrelated (n ¼ 38) allogeneic SCT. Mean recipient age was 23 years (range: 1-60) and median follow-up was 18 months (range: 1-133). Fortythree patients were transplanted in CR1; 25 in CR2 or CR3; four were primary refractory; four in PR; eight in relapse. The conditioning regimen consisted of TBI/ VP16/CY (n ¼ 76), TBI/VP16 (n ¼ 2), TBI/CY (n ¼ 2), Bu/VP16/CY (n ¼ 4). The OS at 3 years was 45% (44% unrelated, 46% related). Univariate analysis showed a significantly better OS for patients o18 years (P ¼ 0.03), mismatched sex-combination (P ¼ 0.03), both with a stronger effect on increasing OS after unrelated SCT. Factors decreasing TRM were patient age o18 years (P ¼ 0.004), patient CMV-seronegativity (P ¼ 0.014), female recipient (P ¼ 0.04). There was no significant difference in TRM and the relapse rate was similar in both donor type groups. Multivariate analysis showed that factors for increased OS which remained significant were mismatched sex-combination (RR: 0.70,95% CI: 0.51-0.93, P ¼ 0.015), patient age o 18 years (RR: 0.66, 95% CI: 0.47-0.93, P ¼ 0.016). A decreased TRM was found for female patients (RR: 0.56, 95% CI: 0.33-0.98, P ¼ 0.042), negative CMV status of the patient (RR: 0.57, 95% CI: 0.36-0.90, P ¼ 0.015). Unrelated stem cell transplantation for high-risk ALL patients with no HLAcompatible family donor is justifiable.
Introduction
There is extensive agreement favoring stem cell transplantation from a related donor over chemotherapy for the treatment of ALL in second remission (CR2) and, if a compatible related donor is available, in high risk and very high risk patients in first remission (CR1). [1] [2] [3] [4] Allogeneic transplantation is also the only therapeutic option which is able to cure patients with hematological malignancies who do not respond to chemotherapy. A potential cure rate of 15-20% of patients with hematological malignancies with nonremission status is described. 5, 6 However, only one fifth to one third of patients who might benefit from this procedure has a HLA-identical sibling.
Unrelated donors from national and international stem cell donor registries are a possible alternative source of graft. The probability of finding an at least HLA-A, B, DR matched donor worldwide is currently about 80%.
Whether stem cell transplantation from an unrelated donor could be a treatment option of equal value in a case lacking a compatible related donor remains controversial. [7] [8] [9] [10] Initial results of unrelated donor transplants were not altogether encouraging because of high-toxic mortality rates and high incidences of severe graft-versus-host-disease (GvHD). 11, 12 A higher incidence of opportunistic infections after unrelated BMT which seemed to be partly due to the influence of micro-and macro-HLA-disparities between donor and host, the intensified myeloablative conditioning and the higher incidence of severe acute and chronic GvHD, are also described. [13] [14] [15] [16] With additional genomic typing of HLA class II antigens more accurate matching has been achieved which was associated with decreased mortality and lower incidence of severe GvHD after unrelated bone marrow transplantation. 13, 17 In vivo T-cell depletion with antithymocyte globulin (ATG) administered as part of the preparative regimen in unrelated stem cell transplantation reduces the risk of severe acute and chronic GvHD and graft failure, without an obvious increase in relapse, as recently demonstrated at our institute. 18, 19 The development of regimens to prevent fatal opportunistic infections, such as Cytomegalovirus, Epstein-Barr virus infection and Pneumocystis carinii has also improved treatment-related mortality (TRM) after allogeneic stem cell transplantation. [20] [21] [22] [23] [24] This report describes our single-center experience of 84 allogeneic stem cell transplants performed in patients with high risk and very high-risk ALL between 1990 and end of 2001. We compared risk factor effects concerning OS, DFS, TRM and relapse rate between stem cell recipients from related and unrelated donors.
Patients and methods
Between September 1990 and November 2001, 84 patients (54 male and 30 female) with high risk and very high-risk acute lymphoblastic leukemia received allogeneic bone marrow (n ¼ 75) or allogeneic peripheral blood stem cell transplants (n ¼ 9) at the University Hospital of Hamburg. All high risk and very high-risk ALL patients transplanted from related and unrelated donors in Hamburg during the observation time were included into this analysis. Mean recipient age was 23 years (range: 1-60 years). Median follow-up was 18 month (range: 1-133 months). The stem cell source was related bone marrow (BM, n ¼ 44), related peripheral blood stem cells (PBSC, n ¼ 2), unrelated BM (n ¼ 31) or unrelated PBSC (n ¼ 7). According to the German ALL study protocol all adult patients were grouped into high risk, considering adverse prognostic features like white blood cell count 430000/ml (B-precursor ALL) or 100000/ml (T-precursor ALL), remission required more than 28 days of induction therapy, t (4;11) and stage of the disease 4first CR or relapse. Very high risk was defined as t (9; 22) or bcr-abl rearrangement. Preliminary results of 25 adult unrelated SCT have been reported recently. 25 Children were introduced to SCT who had Philadelphia chromosome/bcr-abl positive ALL, t (4;11), relapse or significantly delayed remission achievement. Patient characteristics are summarized in Table 1. HLA-A and -B antigens were typed using serological methods. HLA-DRB1 and -DQB1 alleles were typed using sequence-specific oligonucleotide probes. An unrelated donor search was initiated once the first-degree family members had been excluded as donors. Seventy-five patients were transplanted from fully matched donors (siblings: 36; parents: 2; unrelated: 37). Two transplants were carried out which were HLA-A mismatched, three were HLA-B mismatched and four were HLA-DRB1 mismatched. In eight cases out of the nine HLAmismatched transplants, the donor was related (siblings: 1; parents: 6; child: 1).
Comparing patient clinical characteristics of the two donor groups, they were well balanced regarding diagnoses, patient gender, t (9;22) or bcr-abl rearrangement, disease status and number of transplanted CD34 positive cells. Distribution of patient age groups was not significantly different, although there were more adults in the group transplanted from a related donor (Table 2) .
Conditioning regimen
Seventy-six patients (related n ¼ 42, unrelated n ¼ 34) received conditioning with total body irradiation, 1200 cGY given over three days in six fractions, followed by etoposide (30-45 mg/kg) and cyclophosphamide (100-120 mg/kg). Two patients each received only TBI and etoposide (related n ¼ 1, unrelated n ¼ 1) or TBI and cyclophosphamide (related n ¼ 2, unrelated n ¼ 0). Four patients received busulfan (16 mg/kg), etoposide and cyclophosphamide (related n ¼ 1, unrelated n ¼ 3). Bone marrow or peripheral blood stem cells were reinfused 24-48 h after the last cyclophosphamide dose. No manipulation of the graft was performed. 
GvHD prophylaxis
GvHD prophylaxis consisted of cyclosporine A (CsA, 3 mg/kg, given from day À1 to 6 month post transplantation). The dose of CsA was adjusted to achieve a target serum level of 200-300 ng/ml. CsA was tapered from day 120 and discontinued at day 180. Reasons stopping CsA early were relapse or severe side effects of CsA. After unrelated transplantation, Methotrexate (MTX) was given on the first day post transplantation at a dose of 15 mg/m 2 , while we administered a dose of 10 mg/m 2 at the 3rd, 6th and 11th day to all patients who received the graft before 1997 (n ¼ 6). In 1997 all eight unrelated transplant recipients received MTX only on day þ 1, þ 3 and þ 6 (15, 10, 10 mg/m 2 ). After 1997 all unrelated transplant recipients received 10 mg/m 2 on day þ 1, þ 3 and þ 6 (n ¼ 24). The MTX dose was reduced in cases of impaired liver function or severe mucositis.
Rabbit ATG (Fresenius, Bad Homburg, Germany) was administered to 51 recipients of matched unrelated and mismatched family grafts. A cumulative dose between 45 and 90 mg/kg was administered to 34 patients, given over 12 h on days À3, À2 and À1. Fifteen patients received a cumulative ATG dose of 20-30 mg/kg and two patients had a cumulative dose of 120 mg/kg (given on four consecutive days).
Standard criteria were used for classification of acute and chronic GvHD. 26, 27 The estimated probability of clinically limited or extensive chronic GvHD was evaluated in patients who survived for at least 100 days with sustained engraftment.
Supportive care
During neutropenia all patients were nursed in private rooms with hepa-filtered air. Antibiotic prophylaxis was ofloxacin or ciprofloxacin; antifungal prophylaxis consisted of fluconazole (and amphotericin B in case of prior mycotic infection). Aciclovir was given as herpes virus prophylaxis from day 1 to day 180. P carinii prophylaxis consisted of trimethoprim and sulfamethoxazole or inhalation of pentamidine. Only blood products from CMV-negative donors were given and all blood products were irradiated before infusion. Weekly monitoring of blood and/or urine for CMV by polymerase chain reaction, short-term culture and CMV pp65 antigenemia assay were carried out. Positive test results were classified as CMV infection and patients were treated with ganciclovir (5 mg/kg of body weight intravenously, twice a day), continued until negative test results were obtained. Patients with persistent CMV antigenemia were treated with foscarnet (2 Â 60 mg/kg body weight) or a combination of ganciclovir (5 mg/kg) and foscarnet (90 mg/kg) daily. We defined CMV disease as pneumonia with positive CMV testing in bronchial alveolar lavage (BAL), enteritis or hepatitis with positive histology.
Engraftment
Time to leukocyte engraftment was calculated using the day of stem cell infusion as day 0. The day of engraftment was the first of three consecutive days on which the leukocyte count was higher than 1000/mm 3 . Time to platelet engraftment was calculated similarly to leukocyte engraftment, when the platelet count was higher than 20000/mm 3 , without platelet transfusion.
Regimen-related toxicities
Regimen-related toxicities were found in the cardiac, renal, pulmonary, gastrointestinal, hepatic, and central nervous systems and in the oral mucosa. The basis of toxicity grading was the Bearman score. 28 Veno-occlusive disease (VOD) of the liver was diagnosed and classified according to McDonald, Seattle. 29 
Statistical analysis
Univariate statistical analyses were performed using WinSTAT software (Kalmia Co, USA). Overall survival (OS) and disease-free survival (DFS) were calculated from day 0 of stem cell transplantation to the respective event.
In the case of DFS, data were measured to the day of disease relapse, or death from any cause. Event in OS was death from any cause. These 'time to event' curves were estimated according to the method of Kaplan and Meier. 30 The Gray test was performed for depiction of treatment Unrelated vs related stem cell transplantation in ALL patients J Dahlke et al related mortality and probability of relapse in cumulative incidence curves. Multivariate analyses of OS, DFS and TRM were performed to adjust differences in event time distributions for the effect of several prognostic factors acting simultaneously, using the Cox regression model. 31 Criteria for the selection of covariates which were initially included in the model were parameter with P-value o0.1 or approximately 0.1 calculated on univariate analysis. Improvement of the model occurred by elimination of nonsignificant factors, using a stepwise 'backward process'.
Results

Engraftment
Leukocyte engraftment occurred at a median of 17 days (range: 11-28 days). There was no difference in leukocyte engraftment between the two donor type groups (median: unrelated donor ¼ 17 days; related donor ¼ 18 days). Two patients failed to engraft and underwent a second SCT. Three patients died prior to engraftment.
Toxicity and GvHD
Main toxicity according to the Bearman Score 28 was mucositis grade II. It occurred in all patients and necessitated use of intravenous morphine. Table 3 summarizes type and severity of toxicities. In both donor type groups we only found one patient under the age of 18 years in each with an organ toxicity of grade II or higher (except mucositis). All severe toxicities (grade III/IV) were found in adult recipients of unrelated grafts. Twenty-five patients (30%) showed symptoms of VOD; six patients had mild VOD; 15 moderate VOD; four were classified as severe VOD according to McDonald, Seattle. 32 We found no differences in VOD incidence between the two donor types.
The incidence of acute GvHD was 50% (n ¼ 41); 11 patients had grade I aGvHD (13%); 30 patients developed grade II-IV aGvHD (37%); severe grade III-IV aGvHD was seen in 12 patients (15%) of whom one patient died. Two patients who needed more than one stem cell transplant (SCT) developed aGvHD after the second SCT and were excluded. There was no difference in the 100 day cumulative incidence of grades II-IV aGvHD in comparing stem cell transplantation of unrelated (37%) vs related donors (36%).
Chronic GvHD was observed in 16 patients (23%); seven limited (10%) and nine extensive (13%). Again, we noticed no significant difference in the development of GvHD comparing the two different donor types.
CMV serostatus and infection Eleven (28.9 %) patients with an unrelated stem cell donor had CMV infection of which 10 cases were classified as CMV reactivations (CMV-seropositive prior to transplantation with positive PCR and/or positive pp65 test). In the 'related donor SCT group', we registered eight patients (17.4%) with CMV infection of whom seven were reactivations. Most CMV infections occurred in the group of patients who were CMV-positive before transplantation and who had a seronegative donor (70.6%). CMV pneumonia occurred in two patients who were both CMV-seropositive prior transplantation and had a seronegative donor.
Overall survival
After a median follow-up of 18 months (range: 1-133 months), the estimated OS at 3 years after transplantation for all patients was 45%. The Kaplan-Meier curves of OS for all observed patients after stem cell transplantation from unrelated and related donors (44 and 46% at 3 years) are shown in Figure 1 .
A significantly better outcome was noticed for the whole patient collective under the age of 18 years in the univariate analyses (P ¼ 0.03). The separate depiction of the two different donor type groups produced a decreased estimated OS for adult patients who received unrelated transplants (P ¼ 0.006), while the curves in the group of related transplants were comparable (Figures 2 and 3) .
We further recognized an increased OS for sex mismatched vs sex matched (P ¼ 0.03) while not finding any significantly favorable combination. Table 4 summarizes the P-values of all variables considered in the KaplanMeier estimation of OS, DFS and TRM.
The different probability of OS at 4 years, for patients undergoing allogeneic transplantation in first CR (44.7%) compared with patients transplanted in second or third CR (29.7%; P ¼ 0.20) or in relapse, partial remission or with refractory disease (47.3%; P ¼ 0.58) did not reach statistical significance. When considering remission status, there was no difference in OS between related and unrelated transplant patients in CR1. OS of patients in 4CR1 in Table 3 Regimen related toxicity according to the Bearman score Toxicity Grade I Grade II Grade III Grade IV
Unrelated donor Related donor Unrelated donor Related donor Unrelated donor Related donor Unrelated donor Related donor
Unrelated vs related stem cell transplantation in ALL patients J Dahlke et al the group of related transplant patients (n ¼ 10) were 11% at 4 years, while after unrelated transplantation (n ¼ 15), we found a survival of 45% (P ¼ 0.32).
According to the multivariate analyses, the factors for improved OS which remained significant were sex mismatch between donor and recipient (RR: 0.70, 95% CI: 0.51-0.93, P ¼ 0.015) and age of patient o 18 years, (RR: 0.66, 95% CI 0.47-0.93, P ¼ 0.016) ( Table 5) .
Disease-free survival
The estimated DFSs at 3 years for unrelated and related SCT were 43% (42 and 44%). For the univariate analysis of DFS sex-matching (P ¼ 0.03) and AB0 minor incompatibility (P ¼ 0.02) were found to be prognostic factors for better outcome, but on the multivariate analysis none of these factors remained significant. Univariate subgroup analysis showed a strong interaction between the factors 'type of transplant' and 'patient CMV negativity'. In consideration of that we add an interaction term into the Cox regression model which showed a massive qualitative interaction (RR: 0.52, 95% CI 0.32-0.83, P ¼ 0.0063).
For the question of whether results had improved in recent years, we divided the patients in two cohorts receiving transplants before and after January 1996. DFS at 3 years was 44% for 45 patients undergoing SCT between January 1996 and November 2001 and DFS at 3 years was 41% for 39 patients having a transplant before 1996 (P ¼ 0.91 by log rank analysis).
Treatment-related mortality
Twenty-three patients died of causes other than relapse as a consequence of the treatment. The major cause of TRM was infection, which occurred in 17 cases: bacterial sepsis (unrelated: n ¼ 1, related: n ¼ 5), fungal infections (unrelated: n ¼ 4, related n ¼ 3), viral diseases: cytomegalovirus (unrelated: n ¼ 1, related: n ¼ 1); Epstein-Barr virus (unrelated: n ¼ 2, related n ¼ 0). Death from other causes were pulmonary toxicity (unrelated: n ¼ 2, related: n ¼ 0), severe VOD (unrelated: n ¼ 1, related: n ¼ 0), fulminate acute GvHD (unrelated: n ¼ 1, related: n ¼ 0), severe acute pancreatitis (unrelated: n ¼ 0, related: n ¼ 1) and fulminate pulmonary embolism (unrelated: n ¼ 0, related: n ¼ 1). Unrelated vs related stem cell transplantation in ALL patients J Dahlke et al
The univariate analysis (Table 4) found significantly decreased TRM for the group of patients younger than 18 years (P ¼ 0.004), female recipient (P ¼ 0.035), CMVseronegative recipients (P ¼ 0.014) and donor age younger than 20 years (P ¼ 0.043). The donor type again showed no significant influence on cumulative incidence of TRM considering all age groups together (Gray test: P ¼ 0.28; Figure 4 ). Stage of disease or remission was not a prognostic factor for TRM.
A separate view on related and unrelated stem cell transplantation in the univariate analysis showed a marked effect concerning decreased TRM risk of the factor: 'patient age younger than 18 years' in the group with unrelated donors, as shown in Figure 5 (Gray test P ¼ 0.011). In the group of patients younger than 18 years undergoing related stem cell transplantation there was only a tendency to lower TRM (P ¼ 0.07).
The increased TRM seen with patient CMV-seropositivity, only reached significance in the group with related donors (P ¼ 0.004) while in the group with unrelated donors TRM seemed to be unaffected (P ¼ 0.5).
Multivariate analysis (Table 5 ) also found independent prognostic factors for a favorable influence on TRM and supported univariate data for female recipient (RR: 0.56, 95% CI: 0.33-0.98, P ¼ 0.042) and CMV-negativity of the patient (RR: 0.57, 95% CI: 0.36-0.90, P ¼ 0.015). It also showed a tendency for decreased TRM for a mismatched sex-combination (RR: 0.65, 95% CI: 0.41-1.02, P ¼ 0.059).
Relapse After a median follow-up of 18 months (1-133) 23 relapses occurred (27%). The median period of time to relapse was 168 days (range: 1-34 month) post transplantation.
Comparison of different stages of remission or disease, patient age and the two donor types (Figure 6 ) showed no difference regarding relapse rate. We found no factors, which increased relapse rate significantly on univariate analysis. A trend for a higher relapse rate was seen after sex-matched transplantation only in the unrelated SCT group (unrelated SCT: P ¼ 0.08; related SCT: P ¼ 0.4).
Discussion
This study describes the outcome of patients undergoing SCT from a related (n ¼ 46) or unrelated donor (n ¼ 38) for high risk and very high-risk ALL between 1990 and 2001. Our findings are in some aspects consistent with studies that demonstrate a similar outcome of related and unrelated SCT in high-risk ALL but published data concerning this issue are scarce.
We found no statistically relevant differences in any all age group in estimated OS at 4 years, in either the related (44%) or unrelated (40%) donor transplants.
Bunin et al. 1 monitored 363 children with ALL after bone marrow transplantation from a matched unrelated donor (MUD) in CR2 and reported an OS at 5 years post transplantation of 38%. Cornelissen et al. 8 reporting on 127 adult patients with poor-risk ALL described an OS at 2 years from unrelated transplantation of 40% for patients undergoing BMT in CR1 and 32% at 4 years. Similar, comparative results between related and unrelated SCT in ALL patients have been recently reported by Kiehl et al.
25
analyzing 264 patients in a German multicenter study.
The fact that we did not observe any significant difference between patients transplanted in CR1, 4CR1 or with a refractory, relapsed disease or in partial remission (RRP) regarding to OS, DFS, TRM and relapse rate may be due to the small number of patients in this subgroup analysis. The similar outcome of the RRP group in particular is in contrast to several extensive published studies which found unfavorable results for ALL patients who were not in CR at the time of transplant (o10-20% DFS). 3, 33, 34 It is important to note that we found no significant differences between the two donor types. The favorable OS of patients receiving unrelated grafts in 4CR1 should be mentioned but again due to the small number of patients, conclusions should not yet be drawn from this.
In accordance with several published studies, we also found a significant effect of patient age at the time of transplantation on the OS. 1, 25, 35 In our study the separate analysis of the two different donor type groups produced a marked effect on OS in patients after unrelated transplantation (OS: 62% at 3 years for patients up to 18 years vs 17% for patients 418 years), while the group of related transplants showed an approximately equal OS. Further investigations revealed a highly significant increase in TRM in the cohort of recipients after unrelated transplantation 418 years. The relapse rate was similar for both donor types. The relatively high rate of TRM in this subgroup is multifactorial. We recognized an increase in fatal infectious complications and a high rate of organ toxicities due to the conditioning chemotherapy. This raises the question of how to modify the treatment especially in the group of adult patients receiving an unrelated graft. Our main conditioning regimen was TBI, Cyclophosphamide and etoposide, which has a strong myeloablative effect and a high risk for organ toxicities. Keeping in mind that a graft-versusleukemia effect may exist after allogeneic SCT in ALL patients, one way to achieve better results may be to use a reduced dose conditioning regimen. 25, 36 However, data concerning this issue is still scarce. One early study evaluating a less aggressive conditioning regimen in highrisk ALL patients showed relatively reliable engraftment, but still with a high TRM. 37 As confirmed in other studies, CMV neg patients had a better OS and a significantly lower TRM. 21, 32, 38 Our data showed significance concerning TRM only in the related donor SCT group. Again one has to keep in mind that we monitored a relatively small number of patients, which may be behind our finding of a strong negative interaction of the factors 'type of transplant' and 'patient CMV neg' on the multivariate analysis.
T-Cell depletion is a known risk factor for CMV reactivity and disease. 21, [39] [40] [41] We did not observe any significant increase in reactivation when comparing patients who received ATG with those who did not. CMV positivity may be an independent risk factor for TRM, regardless of reactivation or nonreactivation. 21 CMV infection and CMV-related disease are major complications after allogeneic stem cell transplantation with a high mortality rate, especially in cases of interstitial pneumonia. 42, 43 The independent prognostic importance of sex-combination with a favorable outcome for a gender-mismatch between recipient and donor (RR: 0.70; CI 95%: 0.52-0.95, P ¼ 0.023) showed no significance in the comparison of the different recipient/donor combinations. We only found a trend for an increased OS in the group of male stem cell recipients from female donors. This combination is previously described in risk assessments of large EBMT multi-center studies as a significant pretransplant prognostic factor for ALL patients with early hematopoietic stem cell transplantation in CR1, 35 and also for CML patients. 44 Some studies have described an increased incidence of acute and chronic GvHD with female donors, particularly when the recipient is male. [45] [46] [47] It is possible that this gender combination also increases the graft-versus-leukaemia effect and therefore lowers relapse rate. As expected, we again saw a stronger effect of gender mismatch on OS and relapse rate in the group of recipients after stem cell transplantation from unrelated donors.
In summary, similar OS, DFS, TRM and probability of relapse have been observed in patients undergoing related or unrelated SCT for HR ALL at our institution. Nevertheless, there are some risk factors of different value for outcome especially when comparing patients after related and unrelated SCT and considering the different age groups of recipients. Whether or not we should switch to a less aggressive conditioning regimen in adult patients with an unrelated donor in order to reduce TRM for a better OS is still unclear. Some studies describe a benefit of TBI-based conditioning in comparison with busulfan-containing conditioning with regard to DFS and relapse rate 25, 48 suggesting that conditioning should include TBI, if possible. However, more studies with larger numbers of patients receiving a comparable treatment regimen are required.
